Graphite Bio(US:GRPH)2025-11-05 13:23FDA Approval and Product Launch - VIZZ (aceclidine ophthalmic solution) 1.44% received FDA approval for presbyopia treatment, impacting approximately 128 million adults in the U.S.[2] - Over 2,500 Eye Care Professionals (ECPs) have prescribed VIZZ, with 40% prescribing multiple times, resulting in over 5,000 prescriptions filled through October 2025[1][9] - A partnership with Sarah Jessica Parker as a direct-to-consumer campaign spokesperson is set to launch in Q1 2026[1][9] Financial Performance - Net loss for Q3 2025 was $16.7 million, or $0.59 per share, compared to a net loss of $10.2 million, or $0.38 per share, in Q3 2024[7] - Total revenue for Q3 2025 was $12.5 million, with license revenue contributing $12.5 million, compared to no revenue in Q3 2024[22] - Total operating expenses for the nine months ended September 30, 2025, were $70.2 million, compared to $43.4 million during the same period in 2024[22] Expenses Overview - Selling, General and Administrative (SG&A) expenses increased to $27.6 million for Q3 2025, compared to $6.5 million in Q3 2024, primarily due to increased personnel-related expenses[5] - Research and Development (R&D) expenses decreased to $3.8 million for Q3 2025, down from $6.5 million in Q3 2024, driven by reduced clinical trial-related expenses[6] Cash Position and Funding - Pro forma cash, cash equivalents, and marketable securities were approximately $324.0 million as of September 30, 2025, anticipated to fund operations to post-launch positive cash flow[4] - The company achieved $10 million in milestone payments under its agreement with CORXEL Pharmaceuticals in China, including NDA submission for LNZ100[9]